Lilly's Omvoh Hits Composite Endpoints in IBD, But Core Thesis Unchanged

What happened

Lilly reported new one-year composite outcomes for Omvoh (mirikizumab) in ulcerative colitis and Crohn's disease, showing 27.7% comprehensive disease control in UC and 20.4% corticosteroid-free deep remission in Crohn's, including in patients with prior biologic failure. These data are clinically meaningful and support Omvoh's differentiation in inflammatory bowel disease, but IBD represents a much smaller revenue opportunity than Lilly's dominant incretin franchise. Omvoh was not listed among the top-selling products in the latest 10-Q, indicating its financial contribution is currently modest relative to Mounjaro and Zepbound. While this data may bolster Lilly's immunology portfolio over time, it does not address the critical uncertainties around obesity pricing pressure, Foundayo ramp, or Medicare uptake that drive the investment thesis. Overall, this is a positive incremental data point with limited near-term financial impact.

Implication

For investors, this data reinforces Lilly's ability to generate differentiated clinical evidence, but it does not change the WAIT rating or valuation framework. The core investment case still hinges on obesity franchise execution, particularly Foundayo adoption and Medicare Bridge uptake, which remain unresolved. Omvoh's IBD market is competitive and smaller in scale compared to cardiometabolic, so this news should not be overweighted. Investors should continue to focus on upcoming quarterly updates on incretin pricing and volume trends rather than peripheral pipeline data. The stock's premium valuation of 38x earnings requires proof of sustained obesity growth, not incremental immunology wins.

Thesis delta

The thesis remains unchanged: Lilly is a WAIT based on obesity franchise dynamics, with key catalysts being Foundayo adoption and Medicare Bridge uptake. This Omvoh data does not address those drivers and therefore does not alter the rating or valuation framework. It adds a minor positive to the immunology segment but does not justify a thesis upgrade.